CorMedix (CRMD) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 23, 2026, with voting available online, by mail, or virtually.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of seven directors is on the ballot.
Advisory vote on executive compensation for 2025.
Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2026.
Ratification of Certificate of Designation Amendments.
Amendments to the Charter for technical changes and to update approval processes for preferred stock amendments.
Charter amendment to designate exclusive forums for certain claims.
Charter amendment to limit certain officers' personal liability for monetary damages.
Proposal to allow adjournment of the meeting if more time is needed for voting on key proposals.
Board of directors and corporate governance
Seven nominees listed for election to the board.
Board recommends voting in favor of all proposals.
Latest events from CorMedix
- Proxy details robust 2025 results, major governance updates, and key proposals for shareholder approval.CRMD
Proxy filing29 Apr 2026 - Diversified portfolio and late-stage pipeline drive growth and key clinical milestones.CRMD
Investor Day 202620 Apr 2026 - Proxy outlines 2026 meeting proposals, governance updates, and strong 2025 financial results.CRMD
Proxy filing17 Apr 2026 - REZZAYO phase III data and DefenCath reimbursement reset are key near-term catalysts.CRMD
25th Annual Needham Virtual Healthcare Conference14 Apr 2026 - REZZAYO phase III data and DefenCath expansion drive growth amid a diversified, lean operation.CRMD
The Citizens Life Sciences Conference 202611 Mar 2026 - Diversified specialty pharma advancing REZZAYO and DefenCath, with strong growth catalysts ahead.CRMD
Leerink Global Healthcare Conference 202610 Mar 2026 - Strong growth, diversified portfolio, and expanding pipeline drive sustained value creation.CRMD
Corporate presentation10 Mar 2026 - Q4 2025 net revenue hit $128.6M, with strong profit and robust 2026 outlook.CRMD
Q4 20255 Mar 2026 - DefenCath's rapid commercial success drives profitability and expansion in dialysis and beyond.CRMD
The Citizens JMP Life Sciences Conference 20253 Feb 2026